With its launch of a pilot program for the review of novel excipients, the US Food and Drug Administration is generating excitement over what could become a more workable approval pathway than the drug application process.
Despite the industrywide benefits of novel excipients, it is rare for applicants to complicate their submissions and risk approval delays...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?